Prof. Qing Zhu 朱青
Chief Physician, Professor
Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of pancreatic and bile duct cancers. Chemotherapy, molecular targeted therapy, and comprehensive care for gastric and colorectal cancers.
Dr. Zhu is a Chief Physician, Professor, and Researcher with a medical doctorate and postdoctoral training in the US. A Ministry of Education New Century Excellent Talent, Dr. Zhu has led multiple National Natural Science Foundation projects. In 2019, Dr. Zhu received the Ministry of Education Higher Education Science and Technology Award (Second Class) and a national invention patent. Dr. Zhu co-edited Biliary Tract Tumors: New Theories, Perspectives, and Techniques.
Professional roles
- Reviewer for PLOS One, Oncotarget, Cancer Letter, Cell Cycle, BMC Cancer, Medical Oncology Report, and Journal of Immunology Research
- Editorial Board Member, Austin Proteomics
Name order: in Chinese the family name comes first (Zhu Qing). Papers usually list the name as Qing Zhu or Zhu Q.
Selected publications
69 papers on PubMed matched by name and affiliation; 40 as first or senior author since 2016. Most recent first- or senior-author papers:
- Exp Mol Pathol, 2026 (senior author): Pan-cancer analysis identifies GPRIN1 as a prognostic biomarker and promoter of cell proliferation in pancreatic cancer. PubMed 42372374
- Cancers (Basel), 2026 (senior author): Serum SAMD9 as a Potential Prognostic Biomarker for Pancreatic Cancer. PubMed 42738303
- Oncogene, 2026 (senior author): SPOP-mediated nuclear ubiquitination degradation of p62/SQSTM1 contributes to HR repair. PubMed 42323478
- Transl Oncol, 2026 (senior author): Radiotherapy and immunotherapy for advanced cancers: A meta-analysis of dose, sequencing, and survival patterns. PubMed 42068676
- Precis Clin Med, 2026 (senior author): Agrimol B inhibits pancreatic ductal adenocarcinoma by induction of lethal mitophagy through decreasing mitochondrial transcription termination factor 3. PubMed 41978696
- Cancer Lett, 2026 (senior author): circPLEKHM1 promotes tumor growth and metastasis through enhancing FXR1-mediated protein translation in PDAC. PubMed 41794277
- Curr Oncol, 2026 (senior author): E2F1-Driven WDHD1 Transcription Enhances Cell-Cycle Progression and Promotes Pancreatic Cancer Progression. PubMed 42041705
- Biochim Biophys Acta Rev Cancer, 2025 (senior author): Epigenetic mechanisms in non-small cell lung cancer therapy and chemoresistance. PubMed 40446969
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion